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Abstract: Cancer progression is linked to abnormal epigenetic alterations such as DNA methylation
and histone modifications. Since epigenetic alterations, unlike genetic changes, are heritable and
reversible, they have been considered as interesting targets for cancer prevention and therapy by
dietary compounds such as luteolin. In this study, epigenetic modulatory behaviour of luteolin was
analysed on HeLa cells. Various assays including colony forming and migration assays, followed
by biochemical assays of epigenetic enzymes including DNA methyltransferase, histone methyl
transferase, histone acetyl transferase, and histone deacetylases assays were performed. Furthermore,
global DNA methylation and methylation-specific PCR for examining the methylation status of CpG
promoters of various tumour suppressor genes (TSGs) and the expression of these TSGs at transcript
and protein level were performed. It was observed that luteolin inhibited migration and colony
formation in HeLa cells. It also modulated DNA methylation at promoters of TSGs and the enzymatic
activity of DNMT, HDAC, HMT, and HAT and reduced the global DNA methylation. Decrease in
methylation resulted in the reactivation of silenced tumour suppressor genes including FHIT, DAPK1,
PTEN, CDH1, SOCS1, TIMPS, VHL, TP53, TP73, etc. Hence, luteolin-targeted epigenetic alterations
provide a promising approach for cancer prevention and intervention.
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1. Introduction
Cancer chemoprevention is the use of compounds that are natural, synthetic, or
chemical to reverse, retard, or prevent the onset of cancer using mechanisms that kill
malignant cells selectively and spare normal cells [1,2]. These cancer chemopreventive
agents can act at all three stages of cancer development—namely, initiation, promotion,
and progression. FDA approved chemopreventives such as tamoxifen and raloxifene have
the major side effect of causing blood clotting; similarly, tamoxifen—if given for prolonged
period—can lead to endometrial cancer. Hence, researchers are shifting their focus towards
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plant-derived chemopreventive agents, as they have few or no side effects, are more
affordable, easily available, and well tolerated. Studies indicate that dietary bioactive
compounds such as polyphenols, isothiocyanates, etc. are found to have a profound effect
on cancer cells and act via targeting various hallmarks of cancer, leading to the reversal of
carcinogenesis [1,3,4]. Various phenolic agents such as EGCG (epigallocatechin gallate),
curcumin, etc. have been reported to exert antiproliferation, apoptosis-inducing, and
antioxidant properties and to restore the function of TSGs by targeting various molecular
targets and pathways [1,4–6].
Cumulative data, both experimental and epidemiological, approves the utilization of
dietary phytochemicals in chemoprevention, while suggesting that regular consumption
of these phytochemicals is a promising new method for cancer prevention [7]. Evidence
from many scientific reports have indicated that various bioactive compounds found in
vegetables and fruits influence epigenetic modulations by regulating crucial processes that
entail tumour suppressor genes reactivation, oncogene suppression, cell-survival protein
activation, and apoptosis induction in various cancers [8]. Several nutrients in our daily
dietary intake play an important role in DNA methylation either by modulating (DNA
methyl transferase) DNMT expression or by altering the presence of methyl donors [8].
Dietary bioactive compounds such as curcumin, tea polyphenols, sulforaphane (SFN),
genistein, resveratrol, and others have been found to be effective against cancer cells by
altering regulatory mechanisms that directly affect the epigenome [9]. Bioactive agents act
upon cancer progression and reverse the process by interfering with the action of (histone
deacetylases) HDACs, DNMTs, and HATs (histone acetyl transferase) [8–11]. Published
reports of polyphenol show that they are able to modify chromatin structure and reactivate
silenced genes [12,13], potentially reverting malignancy-associated epigenetic alterations in
cell lines [2,14]. Hence, modulation of epigenetic mechanisms poses a prominent target for
cancer therapeutics [15]. This multidimensional molecular approach of polyphenols can be
substantially highlighted for cancer prevention and therapy. Polyphenols have shown the
inhibition of proliferation, invasion, and modulation of epigenetic pathways in different
cell lines [16–18].
Luteolin, a flavone, has been studied as an anticancer agent and is known to inhibit
tumour development in cancer cells by inducing apoptosis, inhibiting metastasis by modulation of different pathways such as AKT, MAPK, etc. [19–24]. Luteolin has also shown
anti-invasive and epigenetic modulatory action such as modulation of methylation and
inhibition of HDAC on different cell lines [17,25,26]. In addition to this, flavones have
shown a remarkable safety profile (zero toxicity at up to 140 g/day) with no adverse
side effects [21]. However, few studies are available on epigenetics modulation such as
DNA methylation and histone modifications by DNMT, HMT, and HDAC after luteolin
treatment [25,27,28]. Hence, this study was intended to provide experimental evidence of
luteolin-mediated changes, targeting its antimigratory and chromatin modulatory nature
on HeLa cells for cancer prevention and treatment.
2. Results
2.1. Luteolin Reduces Methylation of Promoter Tumour Suppressor Genes
Luteolin expressively decreased the methylation of crucial tumour suppressor genes
in genome of HeLa cells, including APC, BRCA1, CDH13, CDKN2, MGMT, MLH1, RARB,
RASSF1, and TIMP3. The methylation percentage decreased significantly after treatment
with 10 and 20 µM for 48 h. The values at 10 and 20 µM luteolin treatment for 48 h were
respectively: APC (21%, 5%); BRCA1 (24%, 17%); CDH1 (36%, 22%); CDH13 (36%, 4%);
CDKN2A (23%, 6%); DAPK1 (23%, 13%); FHIT (8%, 2%); GSTP1 (22%, 3%); MGMT (29%,
5%) MLH1 (23%, 4%); PTEN (19%, 4%); RARβ (30%, 5%); RASSF1 (28%, 10%); SOCS1 (82%,
63%); TIMP3 (18%, 5%);VHL (26%, 5%); WIFI (63%, 28%); and TP73 (79.9%, 39.5%), as
compared with the untreated controls, where the methylation percentage was much higher
(Figure 1A).
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Figure 1.
1. (A).
(A). Luteolin
Luteolin treatment
treatment of
of HeLa
HeLa cells
cells at
at 10
10 and
and 20
20 µM
µM for
for 48
48 hhdemonstrated
demonstrated profound
profound
Figure
decrease in percentage methylation in 5′ 0CpG promoter regions of TSGs, as compared with the undecrease in percentage methylation in 5 CpG promoter regions of TSGs, as compared with the
treated controls, in a dose-dependent manner ( * represents that data is statistically significant with
untreated controls, in a dose-dependent manner (* represents that data is statistically significant with
p ≤ 0.05). (B). Luteolin decreased global DNA methylation in HeLa cells. The data are presented as
pmean
≤ 0.05).
(B). Luteolin
decreased
global DNA
HeLa
The data are
presented
as
of three
independent
experiments
± SD methylation
(* representsin
that
datacells.
is statistically
significant
with
mean
of
three
independent
experiments
±
SD
(*
represents
that
data
is
statistically
significant
with
p ≤ 0.05).(C). Luteolin decreased DNMT activity in HeLa cells in a concentration-dependent manner.
pThe
≤ 0.05).
(C).ofLuteolin
decreased
DNMT activity
HeLa cellsand
in athe
concentration-dependent
manner.
activity
the treated
was compared
with theinuntreated,
values plotted are the mean
of
three
experiments
±
SD
(*
represents
that
data
is
statistically
significant
with
p
≤
0.05).
The activity of the treated was compared with the untreated, and the values plotted are the mean of
three experiments ± SD (* represents that data is statistically significant with p ≤ 0.05).
2.2. Luteolin Diminishes Global DNA Methylation of HeLa Cells
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(Figure1B).
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DNMT Activity
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Incubation
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DNMT activity
activity
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(Figure 1C).
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by 35%,
35%, 57%,
57%, and
and 66%,
66%, respectively,
respectively, in
in comparison
comparison with
with the
the untreated
untreated control
control (Figure
2.4. Luteolin Modulates Migration/Inflammation Related and Tumour Suppressor Genes
2.3. Luteolin Modulates Migration/Inflammation Related and Tumour Suppressor Genes
The decreased methylation percentage of various tumour suppressor genes after
The decreased methylation percentage of various tumour suppressor genes after luluteolin treatment was further verified by checking the expression of these genes using
teolin treatment was further verified by checking the expression of these genes using
quantitative RT PCR. It was observed that luteolin increased the expression of various TSGs
quantitative RT PCR. It was observed that luteolin increased the expression of various
and the relative quantity (RQ) values after 10 and 20 µM treatment of HeLa cells for 48 h,
TSGs and the relative quantity (RQ) values after 10 and 20 µM treatment of HeLa cells for
respectively, for VHL (RQ 7, 9); TIMP3 (RQ 4.5, 5.6); TIMP4 (RQ 6, 10); PTEN (RQ 2, 4.0);
48 h, respectively, for VHL (RQ 7, 9); TIMP3 (RQ 4.5, 5.6); TIMP4 (RQ 6, 10); PTEN (RQ 2,
RARB (RQ 1.78,3.5); SOCS1 (RQ 2.65, 3.6); FHIT (RQ 1.5, 2.8); and GSTP1 (RQ 1.5, 1.8) and
4.0); RARB (RQ 1.78,3.5); SOCS1 (RQ 2.65, 3.6); FHIT (RQ 1.5, 2.8); and GSTP1 (RQ 1.5, 1.8)
at the same time decreased the expression of various migration related genes such as MMP2
and at the same time decreased the expression of various migration related genes such as
(RQ 0.53, 0.31); MMP9 (RQ 0.34, 0.38); MMP14 (RQ 0.28, 0.07); SNAIL2 (RQ 0.56, 0.45);
MMP2 (RQ 0.53, 0.31); MMP9 (RQ 0.34, 0.38); MMP14 (RQ 0.28, 0.07); SNAIL2 (RQ 0.56,
SMAD4 (RQ 0.26, 0.12); MTA1 (RQ 0.41,0.16); MTA2 (RQ 0.42, 0.13); and TGFB1 (RQ 0.50,
0.20), as well as oncogenes JUN (RQ 0.27, 0.21) and MYC (RQ 0.38, 0.07) (Figure 2A).
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Figure
Figure2.2.(A).
(A).Luteolin
Luteolinmodulated
modulatedthe
theexpression
expressionof
ofvarious
variousTSGs
TSGsand
andmigration
migrationrelated
relatedgenes
genesin
inaa
dose-dependent manner. The TSGs were upregulated, whereas inflammatory and migration-related
dose-dependent manner. The TSGs were upregulated, whereas inflammatory and migration-related
genes were downregulated. (B). Luteolin inhibited HDAC activity in HeLa cells in a concentrationgenes were downregulated. (B). Luteolin inhibited HDAC activity in HeLa cells in a concentrationdependent manner in comparison with the untreated control. The values were taken as mean of
dependent
manner± in
with
untreated
control.
The values
were
mean
of three
three
experiments
SDcomparison
(* represents
thatthe
data
is statistically
significant
with
p ≤taken
0.05).as
(C).
Treatment
experiments
±
SD
(*
represents
that
data
is
statistically
significant
with
p
≤
0.05).
(C).
Treatment
of
of HeLa cells with luteolin at 10 and 20 µM for 48 h modulated the expression of epigenetic enzymes
HeLa
cells
with
luteolin
at
10
and
20
µM
for
48
h
modulated
the
expression
of
epigenetic
enzymes
in
in a dose-dependent manner (* represents that data is statistically significant with p ≤ 0.05).
a dose-dependent manner (* represents that data is statistically significant with p ≤ 0.05).

2.4. Luteolin Decreases HDAC Activity in HeLa Cells
2.5. Luteolin Decreases HDAC Activity in HeLa Cells
Histone deacetylation leads to heterochromatin and thus reduced gene expression,
Histone deacetylation leads to heterochromatin and thus reduced gene expression, so
so the activity of histone deacetylases was analysed after direct incubation of nuclear exthe activity of histone deacetylases was analysed after direct incubation of nuclear extracts
tracts with different concentrations of luteolin. Incubation of the nuclear extract with 5,
with different concentrations of luteolin. Incubation of the nuclear extract with 5, 10, and
10, and 20 µM luteolin led to decreased HDAC activity by 28%, 40%, and 55%, respec20 µM luteolin led to decreased HDAC activity by 28%, 40%, and 55%, respectively, as
tively, as compared with the controls, as shown in Figure 2B.
compared with the controls, as shown in Figure 2B.

2.5.
2.6.Luteolin
LuteolinTreatment
TreatmentModulates
Modulates the
the Expression
Expression of
of Chromatin-Modifying
Chromatin-Modifying Genes
Genes
Luteolin
treatment
of
HeLa
cells
modifies
the
expression
of
various
chromatin-modLuteolin treatment of HeLa cells modifies the expression of various chromatin-modifying
ifying
enzymes.
Luteolin
treatment
downregulated
the
chromatin-modifying
enzymes,
enzymes. Luteolin treatment downregulated the chromatin-modifying enzymes,
and the
and
the
RQ
values
after
treatment
of
10
and
20
µM
for
48
h,
respectively,
were
RQ values after treatment of 10 and 20 µM for 48 h, respectively, were DNMT1 DNMT1
(RQ 0.20,
(RQ
0.20,
0,05), DNMT3A
and DNMT3B
(RQ 0.16,
0.10),
where downreg0.05),
DNMT3A
(RQ 0.37, (RQ
0.18),0.37,
and 0.18),
DNMT3B
(RQ 0.16, 0.10),
where
downregulated;
addiulated;
additionally,
HDAC1
(RQ
0.37,
16),
HDAC7
(RQ
0.38,
0.10),
HDAC2
0.33,
0.12),
tionally, HDAC1 (RQ 0.37, 16), HDAC7 (RQ 0.38, 0.10), HDAC2 (RQ 0.33, (RQ
0.12),
HDAC11
HDAC11
0.15),(RQ
HDAC10
(RQ EHMT2
0.24, 0.14)
(RQESCO1
0.10, 0.03),
(0.09,
(RQ 0.39, (RQ
0.15),0.39,
HDAC10
0.24, 0.14)
(RQEHMT2
0.10, 0.03),
(0.09, ESCO1
0.03), AURKA
0.03),
AURKA
0.27, 0.04),
AURKB
0.32, 0.03),
AURKC
0.33,
0.13),
(RQ 0.27,
0.04),(RQ
AURKB
(RQ 0.32,
0.03),(RQ
AURKC
(RQ 0.33,
0.13),(RQ
KAT8
(RQ
0.12,KAT8
0.06),(RQ
and
0.12,
0.06),
and
HAT1
(RQ
0.37,
0.17)
were
all
downregulated
after
treatment
of
the
HeLa
HAT1 (RQ 0.37, 0.17) were all downregulated after treatment of the HeLa cells with luteolin
cells
with
10 h.
and
20 µM for
48 h. However,
ESCO2
(RQtransferase),
2.30, 6.5) (acetyl
10 and
20luteolin
µM for 48
However,
ESCO2
(RQ 2.30, 6.5)
(acetyl
CIITAtransfer(RQ 1.6,
ase),
CIITA
(RQ
1.6,
5.5)
(class
II
trans
activator),
and
SETD2
(methyl
transferase)
were
5.5) (class II trans activator), and SETD2 (methyl transferase) were upregulated. Luteolin
upregulated.
Luteolinhistone
also downregulated
histone
methyl
transferases
such
as WHSC1
ASH1L
also downregulated
methyl transferases
such
as ASH1L
(RQ 0.04,
0.03);
(RQ
(RQ(RQ
0.21,0.17,
0.08),
SU2V40H1
(RQ 0.17,
0.12),USP1
and ubiquitin
enzyme
(RQ0.04,
0.21, 0.03);
0.08), WHSC1
SU2V40H1
0.12),
and ubiquitin
enzyme
(Figure 2C).
CIITA
regulates the transcription of major histocompatibility complex (MHC) class I and II genes.
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2.6. Luteolin Reduces the HAT Activity in a Dose-Dependent Manner
2.7. Luteolin
Luteolin Reduces
HAT
in a Dose-Dependent
at 5, 10,the
and
20 Activity
µM treatment
decreased theManner
HAT activity in HeLa cells, as
compared
withat
the
On incubation
of the
the nuclear
extracts
Luteolin
5, untreated
10, and 20controls.
µM treatment
decreased
HAT activity
in with
HeLadifferent
cells, as
compared withofthe
untreated
controls.
incubation
of the
nuclear
extracts
concentrations
luteolin,
such
as 5, 10,On
and
20 µM, there
was
a decrease
in with
HATdifferent
activity
concentrations
of luteolin,
such as 5, 10,
and 20 µM, there
wasuntreated
a decreasecontrols
in HAT (Figure
activity
by
17%, 51%, and
66%, respectively,
in comparison
with the
by 17%, 51%, and 66%, respectively, in comparison with the untreated controls (Figure 3A).
3A).

Figure 3. (A). Luteolin treatment of 5, 10, and 20 µM decreased the HAT activity in comparison with
Figure
3. (A).control.
LuteolinThe
treatment
of 5, made
10, andas20mean
µM decreased
the HAT activity
the
untreated
plots were
of three experiments
± SDin((*comparison
represents with
that
the
untreated
control.
The
plots
were
made
as
mean
of
three
experiments
±
SD
((*
represents
data
data is statistically significant with p ≤ 0.05). (B). Luteolin treatment decreased HMT H3K9 that
enzyme
is statistically
significant
with
p ≤ 0.05).
(B).untreated
Luteolin treatment
decreased
HMT was
H3K9performed
enzyme activity
activity
in HeLa
cells with
respect
to the
control. The
experiment
three
in
HeLa
cells
with
respect
to
the
untreated
control.
The
experiment
was
performed
three
timeswith
and
times and the values were taken as mean ± SD (* represents that data is statistically significant
pthe
≤ 0.05).
(C).
Luteolin
20
µM
treatment
for
48
h
modulates
the
H3acetylation
and
methylation
hisvalues were taken as mean ± SD (* represents that data is statistically significant with p ≤ 0.05).
tone
in20
HeLa
cells, as compared
with the untreated
controls.
(D).
Luteolin 20
µM treatment
(C). marks
Luteolin
µM treatment
for 48 h modulates
the H3acetylation
and
methylation
histone
marks in
for
48
h
modulates
the
H4
acetylation
and
methylation
histone
marks,
as
compared
the unHeLa cells, as compared with the untreated controls. (D). Luteolin 20 µM treatment for 48with
h modulates
treated
controls.
the H4 acetylation and methylation histone marks, as compared with the untreated controls.

2.8.Luteolin
LuteolinDecreases
Decreasesthe
theHMT
HMTH3K9
H3K9Enzyme
EnzymeActivity
Activity in
in HeLa
HeLa Cells
Cells
2.7.
Histonemethyl
methyl transferase
transferase HMT
di-,
and
tri-trimethylation
Histone
HMT H3K9
H3K9enzyme
enzymecauses
causesmono,
mono,
di-,
and
methylaat
histone
3
lysine
9.
These
marks
are
repressors
of
transcription.
H3K9
methylation
and
tion at histone 3 lysine 9. These marks are repressors of transcription. H3K9 methylation
DNA
methylation
are
cooperative
epigenetic
changes
that
complement
each
other
and
are
and DNA methylation are cooperative epigenetic changes that complement each other
responsible
for silencing
of the promoters
of several
treatment
leads to
and
are responsible
for silencing
of the promoters
of genes.
severalLuteolin
genes. Luteolin
treatment
inhibition
of HMTof
byHMT
24%, by
31%,
and31%,
47% and
after47%
incubation
of the nuclear
extract
with
5, 10,
leads
to inhibition
24%,
after incubation
of the
nuclear
extract
and
20
µM
(Figure
3B),
respectively.
The
inhibition
percentage
was
obtained
by
comparing
with 5, 10, and 20 µM (Figure 3B), respectively. The inhibition percentage was obtained
treated
sample
activity
with the
control
sample
activity.
by
comparing
treated
sample
activity
with
the control
sample activity.
2.9. Luteolin Modulated H3 and H4 Histone Marks
2.8. Luteolin Modulated H3 and H4 Histone Marks
Luteolin decreased the expression of H3K9me1, H3K9me2, H3K9me3, H3K27me1,
Luteolin decreased the expression of H3K9me1, H3K9me2, H3K9me3, H3K27me1,
H3K36me2, H3K36me3, H3K79me1, and H3K79me3 marks after treatment of HeLa cells
H3K36me2, H3K36me3, H3K79me1, and H3K79me3 marks after treatment of HeLa cells
with 20 µM for 48 h; similarly, the H3 acetylation marks were diminished after treatment
with 20 µM for 48 h; similarly, the H3 acetylation marks were diminished after treatment
with the 20 µM of luteolin (Figure 3C). H3K9ac and H3K18ac were reduced likewise, and
with
the 20 µM of
luteolin
(Figure
andincluding
H3K18ac were
reduced
likewise,
and
the acetylation
marks
at H4
were 3C).
also H3K9ac
modulated,
H4K5ac,
H4K8ac,
H4K12ac,
the
acetylation
marks
at
H4
were
also
modulated,
including
H4K5ac,
H4K8ac,
H4K12ac,
and H4K16ac. H4 methylation marks including H4K20m1, H4K20m2, and H4K20m3
and
H4K16ac.
H4after
methylation
marks including
H4K20m2, and
H4K20m3
were
were
decreased
chrysin treatment
(FigureH4K20m1,
3D). Phosphorylation
marks
of H3ser28p,
H4ser1p, H4R3m2a, and H4Rm2s were also decreased after treatment of HeLa cells with
luteolin 20 µM for 48 h (Figure 3C,D).
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decreased after chrysin treatment (Figure 3D). Phosphorylation marks of H3ser28p,
H4ser1p, H4R3m2a, and H4Rm2s were also decreased after treatment of HeLa
cells with
6 of 16
luteolin 20 µM for 48 h (Figure 3C,D).
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2.12. Luteolin Inhibits Migration Capacity of HeLa Cells
The migration inhibitory effect of luteolin was further confirmed by transwell assay.
The migration of control cells was used to compare the migration in treated samples. The
width of the wound (in cm) gradually increased in the wells treated with 10 µM for 24 h
and 48 h of luteolin by 7% and 23%, respectively, and increased by 15% and 31% after 20 µM
treatment for 24 h and 48 h, respectively, while the control wells exhibited the inverse, with
width decreasing in a time-dependent manner, by an average of 45% by 24 h and complete
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closure at 48 h (Figure 5B). The migration inhibitory effect of luteolin was further confirmed
assay. The migration of control cells was used to compare the migration
7 of 16in
treated samples. Luteolin decreased the migration capacity of HeLa cells to 18% and 2% at
10 and 20 µM treatment for 48 h in comparison with the control (Figure 5C).

by transwell
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hypomethylation and hypermethylation of specific promoter regions of tumour suppressor genes (TSGs) and genes related to apoptosis and cell migration [30,32]. In spite of the
fact that synthetic inhibitors showed promising results in alteration of these epigenetic
modifications—owing to poor oral availability, toxicity, and lack of specificity—the ongoing search for compounds that are more specific and less toxic continues [32,33]. Interestingly, polyphenols including flavonoids have shown a number of biological activities
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Luteolin has displayed anticancer effects such as induction of apoptosis and induction
of cell cycle in different cell lines [39,40]. It has shown induction of apoptosis via inhibition
of E6/E7 viral proteins in cervical cancer cells [40]. Similar reports of induction of apoptosis
and inhibition of various pathways in HeLa cells after luteolin treatment were visualised in
our earlier study [24], wherein it was seen that luteolin caused differential cytotoxicity towards HeLa cells in comparison with the lymphocytes in the concentration range (1–40 µM).
There were no significant effects of the used luteolin concentration on lymphocytes [24].
The cell viability percentages at 10 and 20 µM were 70% and 50%, respectively. These two
sublethal doses (10 and 20 µM) were taken for further studies. Luteolin inducted cell cycle
arrest and induced apoptosis by decreasing the expression of AKTs, cyclins, CDK2, Bcl-2,
and MCL1, as well as increasing the expression of Bax, caspase-3, 8, and 9, and p21 [24].
However, different levels of cytotoxicity have been observed in different cell lines after
luteolin treatment [25,26,41,42]. Luteolin has shown selective cytotoxicity towards hepatocytes of hepatocellular carcinoma (HCC) rats, as compared with normal hepatocytes [43].
Additionally, some reports have attributed anticancer effect of luteolin to being sensitive
against drug resistant cancer cells [44].
Interestingly some reports have shown inhibition of metastasis in colorectal cancer
(HT-29 and SW480 and downregulation of MMP 2, MMP 3, and MMP 9 via inhibition of
the AKT/PI3K pathway in melanoma cells (A375 cells) after luteolin treatment [37,38]).
Luteolin has depicted increased expression of MiR-26a, which is a regulator of EZH2, and
at the same time, it has inhibited EZH2 and H3K27me3, leading to self-programmed death
and cycle arrest and apoptosis in prostate cancer cells [45]. To understand the epigenetic
modulation by luteolin, DNA methylation and histone modulation was assessed after
luteolin treatment. DNA methylation of TSGs is associated with silencing of the genes
including GSTP1, BRCA1, RARB, MGMT, RASSF1A, and CDKN2A/p16 [46–50]. In the
present study, it was found that luteolin decreased the DNA methylation percentage in
TSGs (Figure 1A). These TSGs are found to be hypermethylated in cervical cancer, hence
leading to loss of their functions [51]. The decrease in methylation at promoters of TSGs
was further affirmed by reduction in DNMT activity by 35%, 57%, and 66% after 5, 10,
and 20 µM luteolin treatment (Figure 1C). Luteolin also showed a decrease in global DNA
methylation to 57%, 50%, and 30% after 5, 10, and 20 µM treatment for 48 h (Figure 1B). The
decrease in methylation of TSGs led to the reactivation of the genes including TP53, GSTP1,
FHIT, SOCS1, RARB, PTEN, TP73, TIMP3, TIMP4, and VHL (Figure 2A) at the transcript
level and E-cadherin and Tp53 at the protein level. Similar results of decrease in DNMT
activity, global DNA methylation, and reactivation of various TSGs has been demonstrated
by other phytochemicals, including luteolin [26,52].
Gene expression is also modulated by histone modifications that lead to hetero chromatin or euchromatin formation. Histone modifications are mediated by epigenetic enzymes such as histone acetylases, deacetylases, methylases, and demethylases which are
found to be aberrantly expressed in cancer cells [53]. Luteolin showed direct inhibition of
the biochemical activity of HDAC, with a sharp decline of 28%, 40%, and 55% at concentrations of 5, 10, and 20 µM (Figure 2B). This was well corelated with the downregulation
of HDAC1, HDAC5, HDAC7, HDAC2, HDAC10, and HDAC11 at transcript level in a
dose-dependent manner (Figure 2C). The results by other scientists on human epithelioid
cancer cells have demonstrated luteolin to be a potent HDAC inhibitor [25,30]. Further, it
was seen that luteolin treatment decreased the expression of HAT 1 at the transcript level
(Figure 2C) and that HAT enzymatic activity also decreased progressively after luteolin
treatment (Figure 3A). Biochemical activity of HMT (H3K9) (Figure 3B) likewise decreased
in a dose-dependent manner up to 47% (20 µM treatment). Biochemical activity of various
histone modifying enzymes was authenticated by expression analysis of the histone methyl
transferases and histone acetyl transferases after luteolin treatment for 48 h (10 and 20 µM),
wherein downregulation of the expression of histone methyl transferases, such as ASH1L
(H3K36me3), EHMT2 (H3K9me3), SUV420H1 (H3K20me2, me3), WHSC1 (H3K36me2), and
acetyl transferase ESCO1 (establishment of sister chromatid cohesion N-acetyltransferase1),
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KAT8 (lysine acetyl transferase 8), (phosphorylases) AURKA, AURKB, and AURKC, and upregulation of the expression of acetyl transferase ESCO2, CIITA, and SETD2 (histone methyl
transferase) was observed (Figure 2C). These enzymes have been implicated in specific
stages of cell migration, cell propagation, or metastasis, as described as follows. ESCO2 has
the ability to knock down MMP2, thus inhibiting migration of cancer cells [54]. SETD2 is a
tumour suppressor leading to trimethylation of H3K36me3, which is a repressive mark [55].
Major histocompatibility complex class II is linked to better prognosis of cancer patients,
and its expression on cancer cells depends on the trans activator CIITA, which is inactivated
in colorectal and gastric cancers [56], hence attributing tumour suppressor function to
CIITA [53]. WHSC1 activates TWIST and thus EMT; hence, its downregulation inhibits
migration [57]. Inhibition of Aurora kinases has been linked to suppression of cell propagation and metastasis [58,59] and to inhibition of the development and progress of many
cancers [60,61]. ESCO1 expression is also linked to cancer progression and metastasis [62].
Hence, downregulation of ESCO1, WHSC1, AURKA, AURKB, and AURKC by luteolin
points towards its antiproliferative and antimigratory role.
The decrease in HAT expression at the transcript and enzyme activity level was
well corelated with of inhibition of H3 acetylation marks, including H3K9ac, H3K18ac,
H3K14ac, and H3K56ac (Figure 3C). Results on the same lines have been reported with
curcumin and anacardic acid, which have shown an inhibitory effect on P300 and CBP [63].
In vitro and in vivo, luteolin has demonstrated similar results of inhibition of histone acetyl
transferase and H3K9 and H3K14 acetylation [64]. The H3 and H4 methylation marks
are linked to transcription activation (e.g., H3 lysine 4 di, tri methylation, H3, lysine 36
trimethylation, H3lysine 79 me1/me2/me3, H4 Arginine me1, H4 lysine 20 me1) or to
transcription repression (e.g., H3 lysine 27 trimethylation and H3 lysine 9 (di and tri
methylation)) [65]. Luteolin treatment decreased the methylation marks such as histone 3
lysine 9 mono, di, tri methylation, histone 3 lysine 27 mono, and tri methylation, histone 3
lysine 36 mono, di, tri methylation and histone 3 lysine 36 mono, di, tri methylation as
well as H3K4me1, H3K4me2, and H3K4me3. The acetylation and methylation marks at
H4 including the H4K5ac, H4k8ac, H4k12ac, H4K16ac H4K20me1, H4K20me1, H4K20me2,
and H4 K20me3 marks were also decreased after treatment with luteolin. Phosphorylation
marks of H3ser28p and H4ser1p were downregulated too (Figure 3D). These findings
further verify the decreased expression of HMTs such as ASH1L (H3K36me3), EHMT2
(H3K9me3), SUV420H1 (H3K20me2, me3), WHSC1 (H3K36me2), and Aurora kinases at
the transcript level (Figure 2C). There is now clear evidence that Aurora B is one of the
major mitotic kinases that phosphorylates H3 at ser10 and ser28 [66]. Thus, decrease in
Aurora kinase A and B explains the decrease in these H3 ser phosphorylases marks after
luteolin treatment. Overexpression of Aurora kinase A is also linked to overexpression
of MMP 7 and MMP 9, inhibition of Aurora kinases inhibits proliferation, migration and
metastasis [58,59,67].
Interestingly, luteolin further verified an antimigration and anti-inflammatory effect
by downregulation of various genes related to migration and inflammation, such as IL2,
ESR1, MMP14, MMP9, MTA1, MTA2, MMP2, SNAIL2, SMAD4, and TWIST1 and increased
expression of PTEN, TIMP3, TIMP4, TP73, VHL, and SOCS1 after luteolin treatment at
10 and 20 µM for 48 h (Figure 2A). TIMP3, TIMP4, and SOCS1 are negative regulators
of MMPs that regulate the migration machinery in HeLa cells. The above findings were
reinforced by similar results at the protein level, wherein luteolin treatment decreased
the inflammatory and migratory proteins such as MMp-2, MMP-3, HO-1/HMOX1, Her1,
HER2, Her4, mesothelin, cathepsin B, MUC1, nectin 4, FOXC2, IL-18 BPa, CCL3/MIP-1α,
CXCL8/IL-8, IL-2 Rα, kallikrein 6, BCL-X, kallikrein 5, kallikrein 3/PSA, and lumican and
upregulated E-cadherin and P53 (Figure 4A,B). E-cadherin expression inhibits migration
and is hypermethylated in cancer cells [68], and P53 is an important TSGs and has a role
in the cellular processes of proliferation and migration [69]. Similar results of inhibition
of migration and invasion by luteolin on melanoma and breast cancer cells were obtained
by other studies [38,70]. Comparable results have been reported with apigenin, wherein it
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increased the expression of cadherin and decreased expression of vimentin in HCT116 and
inhibited migration in MDA-MB-231 by downregulation of SNAIL and N-cadherin [71,72].
The modulation of the proliferative and migratory pathway was further verified by
colony assay, scratch-wound, and invasion assays after 5, 10, and 20 µM treatment of
luteolin. The number of colonies formed decreased from 480 in control to 150 and 50 at 5
and 10 µM for 48 h; however, no colonies could be seen at 20 µM treatment (Figure 5A),
indicating complete cytostatic induction. In scratch wound assay, the increase in wound
width was visualized by 7% and 23% at 10 µM treatment for 24 and 48 h and 15% and 31%
increase in wound width at 20 µM luteolin treatment for 24 and 48 h treatment, respectively
(Figure 5B). This was further supported by transwell assay, wherein luteolin decreased
the migration capacity of HeLa cells to 18% and 2% at 10 and 20 µM treatment for 48 h
(Figure 5C). These findings further supported the downregulation of pro-migratory (MMPs)
genes and upregulation of antimigratory (TIMPs and PTEN) and antiproliferative genes.
Similar results of inhibition of migration and invasion by luteolin in colorectal cells and
squamous cell carcinoma cells were obtained by some authors [37,38,73].
Our study systematically demonstrates the mode of action of luteolin, which involves
downregulating the expression and activity of epigenetic modulators such as DNMTs,
HDACs, HMTs, and HAT, leading to consequential demethylation of promoters of TSGs
and reactivation of TSGs. In addition, luteolin downregulated the expression of genes
related to proliferation and migration, such as MMPS, SNAIL, MTA1, and MTA2, and
upregulated inhibitors of migration such as TIMPs and TSGs such as PTEN.
4. Material and Methods
4.1. Maintenance of Cervical Cancer Calls (HeLa) and Drug Dilution
Human cervical cancer cell line (HeLa) was maintained in DMEM supplemented with
10% FBS and incubated at 37 ◦ C. Luteolin was purchased from Sigma-Aldrich (Merck,
KgaA, Darmstadt, Germany) and a stock of 69.87 mM was prepared with DMSO. Further
concentration of 1mM was prepared and concentrations (1–40 µM) were made.
4.2. Methylation-Specific PCR (MSRE-PCR)
An EpiTect Methyl II PCR kit (catalogue number 335452, Qiagen, Germantown, MD,
USA) was procured. This kit helps in the quantitation of methylated and unmethylated
DNA. Restriction digestion was conducted on 1 µg of genomic DNA (treated and DMSOtreated), and the cleaved DNA in each reaction was measured using quantitative PCR.
The amount of unmethylated and methylated DNA was assessed using the ∆∆ CT technique, which compared the quantity of each reaction to that of a mock (no enzymes added)
response. The gene panel (which included pre-designed primers) included tumour suppressor genes. The mean of three experiments was used to assess statistical significance
(p < 0.05).
4.3. Global DNA Methylation Assay
The DNA of the treated (5, 10, and 20 µM of luteolin for 48 h) and vehicle control
cells was extracted using the GenElute Mammalian Genomic DNA Miniprep Kit (Catalogue number G1N70; Sigma-Aldrich, Merck, KgaA). The quality and quantity of DNA
was checked by gel electrophoresis (1% agarose gel, Catalog No. A9539, Sigma-Aldrich,
Merck, KgaA) and spectrophotometry using Nanodrop 2000 (Thermo Scientific™, Waltham,
MA, USA), respectively. The MethylFlash™ Methylated DNA Quantification Kit (Catalogue number: P-1034; Epigentek, Farmingdale, NY, USA) was used for the detection of
methylated DNA by 5-mC antibody, which can be assessed calorimetrically.
The treated and untreated DNA were investigated for global DNA methylation as per
the protocol. Absorbance was read on an ELISA reader at 450 nm, 10 min after placement
in developing solution. Optical density values are relative to the quantity of methylated
DNA, and the levels of methylation were calculated in comparison with the control. Data
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were taken as the average of 3 experiments ± SD. Significant differences were established
at p ≤ 0.05.
4.4. Expression Analysis of TSGs
GenElute Mammalian Genomic Total RNA Kit, Sigma, Merck, KgaA, was procured.
The manufacturer’s instructions were followed while extracting RNA from luteolin-treated
HeLa (10 and 20 M for 48 h) and untreated cells. The Applied Biosystems High-Capacity
cDNA Reverse Transcription Kit was then used to synthesize cDNA on the RNA. The
expression of various TSGs and genes encoding various pathways was analysed using a
TaqMan-based custom array (4391524). Thermo Fisher’s DataAssistTM software was used
to perform the PCR array on QuantStudio3 and analyse it using the ∆∆ CT technique. ACTB
(Actin Beta) expression was used for normalization.
4.5. Protein Expression by Proteome Profiler Array
Proteome profiler array (catalogue no. ARY026) was procured from R&D, USA. The
treated (10 and 20 µM for 48 h) and untreated cells were collected and resuspended in
lysis buffer 17 (1 mL per 107 cells); the lysate was prepared, and protein concentration was
checked using Pierce BCA Assay (Catalogue no: 23225; Thermo-Fisher Scientific, Waltham,
MA, USA). The signals produced on the membranes were quantified by chemiluminescent
gel doc system (Bio-Rad Laboratories, Hercules, CA, USA) and analysed using Image
Lab software (version 6.1). Significance was calculated by one-way ANOVA using SPSS
software and was documented at p ≤ 0.05.
4.6. Analysis of Epigenetic Enzymes Involved in Chromatin Modification
Human Chromatin Modification Enzymes Array (Catalogue number PAHS-085Z;
Qiagen, MD, USA) was used to check the expression of the genes such as DNMTs, HMTs,
HATS, and HDMs. RNA at a concentration of 1 µg was used to synthesize cDNA, and
it was diluted to 1350 µL with nuclease free water, and an equal amount of RT2 SYBR®
Green qPCR Master mix (Catalogue number: 330504; Qiagen, MD, USA) was added to this.
From this mixture, 25 µL was poured into each well of an array plate having pre-defined
primers, and the plate was run on ABI Quant Studio 3. The normalization was performed
using GAPDH as the housekeeping gene, and fold change was calculated by comparing
treated samples with untreated controls. The statistical significance was calculated, and the
significance was established at p ≤ 0.5.
4.7. Nuclear Extract Preparation
Nuclear extracts from HeLa cells were prepared using EpiQuikTM nuclear extraction
kit (Catalogue number OP-0002; Epigentek, NY, USA) as per the manufacturer’s protocol.
Approximately 2 × 106 untreated cells were trypsinised, collected, and centrifuged at
150× g for 10 min. The nuclear extract was prepared and stored at −80 ◦ C until used. The
protein concentration of the nuclear extract was checked using the BCA protocol.
4.8. DNMT Activity Assay
Nuclear extract from untreated HeLa cells was prepared using EpiQuikTM nuclear
extraction kit (Catalogue number OP-0002; Epigentek, NY, USA). The EpiQuik DNMT
activity assay kit (Catalogue number P-3001; Epigentek, NY, USA) was used to check the
effect of the luteolin on DNMT activity. In the sample wells AdoMet (methyl group donor),
nuclear extracts, and different concentrations of luteolin (5, 10, and 20 µM in assay buffer)
were used to check for DNMT activity by following the protocol, whereas assay buffer was
used in controls instead of the inhibitor. After incubating the plate for 2 h and developing
the signal, the plate was read at 450 nm. The percentage of inhibition in comparison with
control was calculated and plotted as a graph. The experiment was repeated thrice and the
mean ± SD was used to plot a graph. One-way ANOVA was used to check for statistical
significance, and p was established at ≤0.05.
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4.9. HDAC Activity Assay
The EpiQuik HDAC activity assay kit (Catalogue number P-4002; Epigentek, NY, USA)
was used to determine the effect of luteolin treatment on HDAC activity. Luteolin (5 µM,
10, and 20 µM), nuclear extract, and HDAC assay buffer were added to the assay plates and
incubated for one hour at 37 ◦ C to allow the action of the enzyme, followed by incubation
with capture and detection antibody. In the controls, luteolin was substituted by assay
buffer. The plate was read on an ELISA reader at 450 nm. Inhibition of HDAC activity
by luteolin was calculated in comparison with control wells. Experiments were repeated
thrice, and the mean ± SD was used to plot as a graph (p ≤ 0.05).
4.10. HMT H3K9 Activity Assay
The EpiQuik HMT H3K9 activity assay kit (Epigentek, NY, USA) was used to check the
effect of luteolin on HMT H3K9 activity by following the manufacturer’s protocol. Briefly,
to histone 3 lysine substrate-coated assay plate biotinylated substrate, assay buffer and
AdoMet were added and incubated for 1.5 h at 37 ◦ C. In the case of test samples, luteolin at
5, 10, and 20 µM was added to the wells. After developing the colour, the absorbance was
read on an ELISA reader at 450 nm. The inhibition of HMT by luteolin in comparison with
the controls was calculated and plotted as a graph. The results were taken as the mean of
3 experiments ± SD (p ≤ 0.05).
4.11. HAT Activity
HAT activity/inhibition kit (catalogue number P-4003, Epigentek, NY, USA) was
procured. Briefly, the nuclear extracts were incubated with the substrate for HAT for
60 min, followed by washing. Luteolin concentrations were added in the test samples.
The experiment was carried out as per the manufacturer’s protocol. The plate was read
at 450 nm on an ELISA plate reader, and the HAT activity inhibition was calculated
from the average of three experiments. The results were calculated as the mean of three
experiments ± SD, (p ≤ 0.05).
4.12. Scratch-Wound Assay
To understand the antimigratory effect of luteolin, the scratch-wound assay was
carried out. The protocol was adapted from our lab [74]. Briefly, almost 5 × 105 cells were
plated in a six-well plate and incubated at 37 ◦ C overnight. Next day a “wound” or a cellfree line was created on a confluent monolayer of cells by scratching the monolayer with a
pipette tip, and the cells were incubated in the presence of different luteolin concentrations
(0, 10, and 20 µM), and the “healing” of the wound, which occurs through cell migration
and growth towards the cell free zone, was monitored after 24 h and 48 h. An inverted
microscope was used to capture images of the wounds in each well prior to treatment and
after 24 h and 48 h of the treatment. The wound width was measured using the paint
software. The change in wound width in comparison with the control was calculated. The
experiment was triplicated, and results expressed ± SD (p < 0.05).
4.13. Colony Forming Assay
Approximately 2.5 × 105 cells were plated in a six well plate and followed by treatment
with different concentrations of luteolin (5, 10, and 20 µM) for 48 h. Treated cells were
collected after 48 h treatment, counted, and plated at approximately 500 cells/well. The
cells were allowed to grow for two weeks. Then, cells were fixed in 100% methanol and
stained with 0.1% crystal violet. The stained colonies were counted and images were taken
using an Olympus inverted microscope (Labomed, Los Angeles, CA, USA), and ImageJ
software was used to count the colonies [75].
4.14. Trans Well Chamber Assay
Briefly, 5.0 × 103 cells/well (both treated and untreated) were seeded on the upper
side of the insert (8 µm pore size, BD Biosciences, Franklin Lakes, NJ, USA), and on the
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lower side of the insert in the 24-well plate, complete media was kept. Cells on the inner
side of the insert were stained with 0.1% crystal violet, and cells on the outer side of the
insert were scraped. Invasive potential of treated and untreated cells was compared, and
the migrated cells were counted by using an inverted microscope (Olympus Corporation,
Tokyo, Japan, 200× magnification). Graphs were plotted after repetition of the experiment
three times, and the results are expressed as mean ± SD (p < 0.05).
4.15. Statistical Analysis
The results of the experiments are expressed as average ± standard deviation of three
experiments. SPSS software version 21.0 was used to check the statistical significance with
one-way ANOVA followed by Tukey’s HSD post hoc analysis.
5. Conclusions
Luteolin acts as a potent antiproliferative, antimigratory agent. It decreased the
50 CpG promoter methylation of various TSGs, leading to re-expression of these TSGs and
inactivated genes related to migration and inflammation. Considering its antimigratory
and epigenetics modulatory behaviours warrants its use as a potential chemopreventive
agent for therapeutic use, but only after clinical trials.
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Paluszczak, J.; Krajka-Kuźniak, V.; Małecka, Z.; Jarmuż, M.; Kostrzewska-Poczekaj, M.; Grenman, R.; Baer-Dubowska, W.
Frequent gene hypermethylation in laryngeal cancer cell lines and the resistance to demethylation induction by plant polyphenols.
Toxicol. Vitr. 2011, 25, 213–221. [CrossRef] [PubMed]
Ptak, C.; Petronis, A. Epigenetics and complex disease: From etiology to new therapeutics. Annu. Rev. Pharmacol. Toxicol. 2008, 48,
257–276. [CrossRef]
Majumdar, D.; Jung, K.-H.; Zhang, H.; Nannapaneni, S.; Wang, X.; Amin, A.R.; Chen, Z.; Shin, D.M. Luteolin nanoparticle in
chemoprevention: In Vitro and In Vivo anticancer activity. Cancer Prev. Res. 2014, 7, 65–73. [CrossRef]
Tuorkey, M.J. Molecular targets of luteolin in cancer. Eur. J. Cancer Prev. 2016, 25, 65. [CrossRef]
Pratheeshkumar, P.; Sreekala, C.; Zhang, Z.; Budhraja, A.; Ding, S.; Son, Y.; Wang, X.; Hitron, A.; Hyun-Jung, K.; Wang, L.; et al.
Cancer prevention with promising natural products: Mechanisms of action and molecular targets. Anti-Cancer Agents Med. Chem.
2012, 12, 1159–1184. [CrossRef]
Lu, Y.; Ruan, J.; Zhang, L.; Yan, L.; Liu, Y.; Yue, Z.; Chen, L.; Wang, A.-Y.; Chen, W.; Zheng, S.; et al. Inhibition of hypoxia-induced
epithelial mesenchymal transition by luteolin in non-small cell lung cancer cells. Mol. Med. Rep. 2012, 6, 232–238. [CrossRef]
Liskova, A.; Koklesova, L.; Samec, M.; Smejkal, K.; Samuel, S.M.; Varghese, E.; Abotaleb, M.; Biringer, K.; Kudela, E.; Danko, J.;
et al. Flavonoids in Cancer Metastasis. Cancers 2020, 12, 1498. [CrossRef]
Amawi, H.; Ashby, C.R., Jr.; Tiwari, A.K. Cancer chemoprevention through dietary flavonoids: What’s limiting? Chin. J. Cancer
2017, 36, 50. [CrossRef] [PubMed]
Raina, R.; Hussain, A.; Sharma, R. Molecular insight into apoptosis mediated by flavones in cancer (Review). World Acad. Sci. J.
2020, 2, 6. [CrossRef]
Ruan, J.-S.; Liu, Y.-P.; Zhang, L.; Yan, L.-G.; Fan, F.-T.; Shen, C.-S.; Wang, A.-Y.; Zheng, S.-Z.; Wang, S.-M.; Lu, Y. Luteolin
reduces the invasive potential of malignant melanoma cells by targeting β3 integrin and the epithelial-mesenchymal transition.
Acta Pharmacol. Sin. 2012, 33, 1325–1331. [CrossRef] [PubMed]
Raina, R.; Almutary, A.G.; Bagabir, S.A.; Afroze, N. Chrysin Modulates Aberrant Epigenetic Variations and Hampers Migratory
Behavior of Human Cervical (HeLa) Cells. Front. Genet. 2021, 12, 768130. [CrossRef]
Attoub, S.; Hassan, A.H.; Vanhoecke, B.; Iratni, R.; Takahashi, T.; Gaben, A.-M.; Bracke, M.; Awad, S.; John, A.; Kamalboor, H.;
et al. Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in
human epithelioid cancer cells. Eur. J. Pharmacol. 2011, 651, 18–25. [CrossRef]
Kanwal, R.; Datt, M.; Liu, X.; Gupta, S. Dietaryflavones as dual inhibitors of DNA methyltransferases and histone methyltransferases. PLoS ONE 2016, 11, e0162956.
Mounira, K.; Antonio, P.; Marc, M.; Leila, C.; Ludovic, L.; Kamel, G. Limoniastrum guyonianum aqueous gall extract induces
apoptosis in colorectal cancer cells by inhibiting calpain activity. Tumor Biol. 2014, 35, 7877–7885.
Zwergel, C.; Valente, S.; Mai, A. DNA Methyltransferases Inhibitors from Natural Sources. Curr. Top. Med. Chem. 2015, 16,
680–696. [CrossRef]
Li, H.-C.; Cao, D.-C.; Liu, Y.; Hou, Y.-F.; Wu, J.; Lu, J.-S.; Di, G.-H.; Liu, G.; Li, F.-M.; Ou, Z.-L.; et al. Prognostic value of matrix
metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res. Treat. 2004,
88, 75–85. [CrossRef]
Busch, C.; Burkard, M.; Leischner, C.; Lauer, U.M.; Frank, J.; Venturelli, S. Epigenetic activities of flavonoids in the prevention and
treatment of cancer. Clin. Epigenet. 2015, 7, 64. [CrossRef]
Grivennikov, S.I.; Greten, F.R.; Karin, M. Immunity, Inflammation, and Cancer. Cell 2010, 140, 883–899. [CrossRef] [PubMed]
Gilbert, E.R.; Liu, D. Flavonoids influence epigenetic-modifying enzyme activity: Structure-function relationships and the
therapeutic potential for cancer. Curr. Med. Chem. 2010, 17, 1756–1768. [CrossRef] [PubMed]
Geneviève, P.; Delcuve, D.H.; Davie, J.R. Roles of histone deacetylases in epigenetic regulation: Emerging paradigms from studies
with inhibitors: Review. Clin. Epigenet. 2012, 4, 5.
Hodek, P.; Trefil, P.; Stiborova, M. Flavonoids-potent and versatile biologically active compounds interacting with cytochromes
P450. Chem. Biol. Interact. 2002, 139, 1–21. [CrossRef]
Malireddy, S.; Kotha, S.R.; Secor, J.D.; Gurney, T.O.; Abbott, J.L.; Maulik, G.; Maddipati, K.R.; Parinandi, N.L. Phytochemical
antioxidants modulate mammalian cellular epigenome: Implications in health and disease. Antioxid. Redox Signal. 2012, 17,
327–339. [CrossRef]
Fang, M.; Chen, D.; Yang, C.S. Dietary polyphenols may affect DNA methylation. J. Nutr. 2007, 137 (Suppl. 1), 223S–228S.
[CrossRef]
Yao, Y.; Rao, C.; Zheng, G.; Wang, S. Luteolin suppresses colorectal cancer cell metastasis via regulation of the miR-384/
pleiotrophin axis. Oncol. Rep. 2019, 42, 131–141. [CrossRef]

Int. J. Mol. Sci. 2022, 23, 4067

38.
39.

40.

41.
42.
43.

44.
45.

46.
47.
48.
49.
50.
51.
52.

53.
54.
55.
56.

57.

58.
59.
60.
61.
62.

15 of 16

Yao, X.; Jiang, W.; Yu, D.; Yan, Z. Luteolin inhibits proliferation and induces apoptosis of human melanoma cells in vivo and
in vitro by suppressing MMP-2 and MMP-9 through the PI3K/AKT pathway. Food Funct. 2019, 10, 703–712. [CrossRef]
Park, S.-H.; Ham, S.; Kwon, T.H.; Kim, M.S.; Lee, D.H.; Kang, J.-W.; Oh, S.-R.; Yoon, D.-Y. Luteolin induces cell cycle arrest and
apoptosis through extrinsic and intrinsic signaling pathways in MCF-7 breast cancer cells. J. Environ. Pathol. Toxicol. Oncol. 2014,
33, 219–231. [CrossRef]
Ham, S.; Kim, K.; Kwon, T.; Bak, Y.; Lee, N.; Song, Y.; Park, S.-H.; Park, Y.; Kim, M.; Kang, J.; et al. Luteolin induces intrinsic
apoptosis via inhibition of E6/E7 oncogenes and activation of extrinsic and intrinsic signaling pathways in HPV-18-associated
cells. Oncol. Rep. 2014, 31, 2683–2691. [CrossRef]
Huang, L.; Jin, K.; Lan, H. Luteolin inhibits cell cycle progression and induces apoptosis of breast cancer cells through downregulation of human telomerase reverse transcriptase. Oncol. Lett. 2019, 17, 3842–3850. [CrossRef] [PubMed]
Lü, X.; Li, Y.; Li, X.; Aisa, H.A. Luteolin induces apoptosis in vitro through suppressing the MAPK and PI3K signaling pathways
in gastric cancer. Oncol. Lett. 2017, 14, 1993–2000. [CrossRef] [PubMed]
Seydi, E.; Salimi, A.; Rasekh, H.R.; Mohsenifar, Z.; Pourahmad, J. Selective cytotoxicity of luteolin and kaempferol on cancerous
hepatocytes obtained from rat model of hepatocellular carcinoma: Involvement of ROS-mediated mitochondrial targeting.
Nutr. Cancer 2018, 70, 594–604. [CrossRef] [PubMed]
Song, S.; Su, Z.; Xu, H.; Niu, M.; Chen, X.; Min, H.; Zhang, B.; Sun, G.; Xie, S.; Wang, H.; et al. Luteolin selectively kills STAT3
highly activated gastric cancer cells through enhancing the binding of STAT3 to SHP-1. Cell Death Dis. 2017, 8, e2612. [CrossRef]
Ganai, S.A.; Sheikh, F.A.; Baba, Z.A.; Mir, M.A.; Mantoo, M.A.; Yatoo, M.A. Anticancer activity of the plant flavonoid luteolin
against preclinical models of various cancers and insights on different signalling mechanisms modulated. Phyther. Res. 2021, 35,
3509–3532. [CrossRef]
Esteller, M. CpG island hypermethylation and tumor suppressor genes: A booming present, a brighter future. Oncogene 2002, 21,
5427–5440. [CrossRef]
Ong, T.P.; Moreno, F.S.; Ross, S.A. Targeting the epigenome with bioactive food components for cancer prevention. J. Nutrigenet.
Nutr. 2012, 4, 275–292. [CrossRef]
Kabekkodu, S.; Chakrabarty, S.; Ghosh, S.; Brand, A.; Satyamoorthy, K. Epigenomics, Pharmacoepigenomics, and Personalized
Medicine in Cervical Cancer. Public Health Genom. 2017, 20, 100–115. [CrossRef]
Soto, D.; Song, C.; McLaughlin-Drubin, M.E. Epigenetic Alterations in Human Papillomavirus-Associated Cancers. Viruses 2017,
9, 248. [CrossRef]
SSiegel, E.M.; Riggs, B.M.; Delmas, A.L.; Koch, A.; Hakam, A.; Brown, K.D. Quantitative DNA methylation analysis of candidate
genes in cervical cancerQuantitative DNA methy. PLoS ONE 2015, 10, e0122495.
Cardoso, M.D.F.S.; Castelletti, C.H.M.; de Lima-Filho, J.L.; Martins, D.B.G.; Teixeira, J.A.C. Putative biomarkers for cervical cancer:
SNVs, methylation and expression profiles. Mutat. Res. -Rev. Mutat. Res. 2017, 773, 161–173. [CrossRef] [PubMed]
Xie, Q.; Bai, Q.; Zou, L.-Y.; Zhang, Q.-Y.; Zhou, Y.; Chang, H.; Yi, L.; Zhu, J.-D.; Mi, M.-T. Genistein inhibits DNA methylation
and increases expression of tumor suppressor genes in human breast cancer cells. Genes Chromosom. Cancer 2014, 53, 422–431.
[CrossRef] [PubMed]
Khan, S.A.; Reddy, D.; Gupta, S. Global histone post-translational modifications and cancer: Biomarkers for diagnosis, prognosis
and treatment? World J. Biol. Chem. 2015, 6, 333. [CrossRef] [PubMed]
Guo, X.-B.; Huang, B.; Pan, Y.-H.; Su, S.-G.; Li, Y. ESCO2 inhibits tumor metastasis via transcriptionally repressing MMP2 in
colorectal cancer. Cancer Manag. Res. 2018, 10, 6157. [CrossRef] [PubMed]
Li, J.; Duns, G.; Westers, H.; Sijmons, R.; van den Berg Anke, K.K. SETD2: An epigenetic modifier with tumor suppressor
functionality. Oncotarget 2016, 7, 50719. [CrossRef] [PubMed]
Satoh, A.; Toyota, M.; Ikeda, H.; Morimoto, Y.; Akino, K.; Mita, H.; Suzuki, H.; Sasaki, Y.; Kanaseki, T.; Takamura, Y.; et al.
Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-γ-induced HLA-DR expression
in colorectal and gastric cancer cells. Oncogene 2004, 23, 8876–8886. [CrossRef] [PubMed]
Ezponda, T.; Popovic, R.; Shah, M.Y.; Martinez-Garcia, E.; Zheng, Y.; Min, D.-J.; Will, C.; Neri, A.; Kelleher, N.L.; Yu, J.; et al. The
histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive
properties of prostate cancer. Oncogene 2013, 32, 2882–2890. [CrossRef]
Romain, C.; Paul, P.; Kim, K.W.; Lee, S.; Qiao, J.; Chung, D.H. Targeting Aurora kinase-A downregulates cell proliferation and
angiogenesis in neuroblastoma. J. Pediatr. Surg. 2014, 49, 159–165. [CrossRef]
Zhu, X.P.; Liu, Z.L.; Peng, A.F.; Zhou, Y.F.; Long, X.H.; Luo, Q.F.; Huang, S.H.; Shu, Y. Inhibition of Aurora-B suppresses
osteosarcoma cell migration and invasion. Exp. Ther. Med. 2014, 7, 560–564. [CrossRef]
Yan, M.; Wang, C.; He, B.; Yang, M.; Tong, M.; Long, Z.; Liu, B.; Peng, F.; Xu, L.; Zhang, Y.; et al. Aurora-A kinase: A
potentoncogene and target for cancer therapy. Med. Res. Rev. 2016, 36, 1036–1079. [CrossRef]
Bavetsias, V.; Linardopoulos, S. Aurora kinase inhibitors: Current status and outlook. Front. Oncol. 2015, 5, 278. [CrossRef]
[PubMed]
Wang, H.; Lu, Y.-J.; Xu, W.-H.; Pang, W.-F.; Zhao, Y.-Y.; Yang, N.; Wang, Z.-P.; Lu, L.; Liu, Y.; Zhang, S.-Y.; et al. The correlation
of ESCO1 expression with a prognosis of prostate cancer and anti-tumor effect of ESCO1 silencing. Transl. Cancer Res. 2019, 8,
950–961. [CrossRef] [PubMed]

Int. J. Mol. Sci. 2022, 23, 4067

63.
64.

65.
66.

67.

68.

69.
70.
71.
72.
73.

74.
75.

16 of 16

Di Cerbo, V.; Schneider, R. Cancers with wrong HATs: The impact of acetylation. Brief. Funct. Genom. 2013, 12, 231–243. [CrossRef]
[PubMed]
Selvi, R.B.; Swaminathan, A.; Chatterjee, S.; Shanmugam, M.K.; Li, F.; Ramakrishnan, G.B.; Siveen, K.S.; Chinnathambi, A.;
Zayed, M.E.; Alharbi, S.A.; et al. Inhibition of p300 Lysine Acetyltransferase activity by Luteolin reduces tumor growth in head
and neck squamous cell carcinoma (HNSCC) xenograft mouse model. Oncotarget 2015, 6, 43806–43818. [CrossRef]
Castillo-Aguilera, O.; Depreux, P.; Halby, L.; Arimondo, P.B.; Goossens, L. DNA Methylation Targeting: The DNMT/HMT
Crosstalk Challenge. Biomolecules 2017, 7, 3. [CrossRef]
Thomson, S.; Clayton, A.L.; Hazzalin, C.A.; Rose, S.; Barratt, M.J.; Mahadevan, L.C. The nucleosomal response associated with
immediate-early gene induction is mediated via alternative MAP kinase cascades: MSK1 as a potential histone H3/HMG-14
kinase. EMBO J. 1999, 18, 4779–4793. [CrossRef]
Chen, C.-H.; Chang, A.Y.W.; Li, S.-H.; Tsai, H.-T.; Shiu, L.-Y.; Shau-Hsuan, L.; Wang, W.-L.; Chiu, T.-J.; Luo, S.-D.; Huang, T.-L.;
et al. Suppression of Aurora-A-FLJ10540 signaling axis prohibits the malignant state of head and neck cancer. Mol. Cancer 2015,
14, 83. [CrossRef]
Holubekova, V.; Mendelová, A.; Grendar, M.; Meršaková, S.; Kapustová, I.; Jašek, K.; Vaňochová, A.; Danko, J.; Lasabová, Z.
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